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Chemistry experimental 
1-Iodo-4-phenylmethoxybenzene (19h). BnBr (389 mg, 4.7 mmol) was added to 19i (1.00 g, 
4.6 mmol) and Cs2CO3 (1.50 g, 4.6 mmol) in dry DMF (10 mL) and the mixture was stirred 
for 90 min. The mixture was diluted with water (10 mL) and extracted thrice with EtOAc. The 
combined extracts were washed (water, brine). Drying and chromatography (petroleum ether / 
EtOAc, 99:1) gave 19h (1.20 g, 82%) as white crystals: mp 59-61°C (lit.
1
 mp 56.5-57C); IR 
max 1582 cm
-1
; 
1
H NMR (CDCl3)  4.99 (2 H, s, CH2), 6.76 (2 H, d, J = 9.0 Hz, 3,5-H2), 
7.31-7.43 (5 H, m, Ph 2,3,4,5,6-H5), 7.56 (2 H, d, J = 9.0 Hz, 2,6-H2); 
13
C NMR (CDCl3)  
70.06 (CH2), 83.01 (4-C), 117.29 (2,6-C2), 127.37 (Ph 3,5-C2), 128.06 (Ph 4-C), 128.59 (Ph 
2,6-C2), 136.50 (Ph 1-C), 138.21 (3,5-C2), 158.61 (1-C). 
4-Methoxy-1-trimethylsilylethynylbenzene (20c). Et3N (10 mL) and THF (10 mL) were 
added to 4-methoxyiodobenzene 19c (1.05 g, 4.5 mmol), CuI (87 mg, 450 mol), 
(Ph3P)2PdCl2 (158 mg, 225 mol) and Na ascorbate (89 mg, 450 mol) under Ar. The mix-
ture was stirred at 40°C for 30 min. Me3SiCCH (1.03 g, 10.5 mmol) was added and the mix-
ture was stirred at 40°C for 16 h. The evaporation residue, in CH2Cl2, was washed (water, 2 
) and dried. Chromatography (petroleum ether / EtOAc 99:1) gave 20c (909 mg, 99%) as an 
oil (lit.
2
 oil): 
1
H NMR (CDCl3)  0.23 (9 H, s, SiMe3), 3.79 (3 H, s, OMe), 6.80 (2 H, d, J = 
6.8 Hz, 3,5-H2), 7.40 (2 H, d, J = 4.9 Hz, 2,6-H2); 
13
C NMR (CDCl3)  -0.002 (SiMe3), 55.17 
(OMe), 92.34 (ethyne 1-C), 105.15 (ethyne 2-C), 113.75 (2,6-C2), 115.25 (4-C), 133.39 (3,5-
C2), 159.70 (1-C); MS m/z 205.1037 (M + H)
+
 (C12H17OSi requires 205.1049). 
4-Trifluoromethyl-1-trimethylsilylethynylbenzene (20d). 4-Trifluoromethyl-1-iodobenzene 
19d was treated with CuI, (Ph3P)2PdCl2, Na ascorbate and Me3SiCCH in THF and Et3N, as 
for the synthesis of 20c, to give 20d (92%) as a colourless oil (lit.
3
 oil): IR max 2161, 2063, 
1614, 1511, 1323 cm
-1
; 
1
H NMR (CDCl3)  0.27 (9 H, s, SiMe3), 7.54 (4 H, s, 2,3,5,6- H4); 
13
C NMR (CDCl3)  -0.02 (SiMe3), 88.07 (ethyne 2-C), 97.13 (ethyne 1-C), 123.90 (q, J = 
272 Hz, CF3), 125.13 (q, J = 3.9 Hz, 3,5-C2), 126.99 (q, J = 1.4 Hz, 1-C), 130.19 (q, J = 32.7 
Hz, 4-C), 132.17 (2,6-C2); 
19
F NMR (CDCl3)  -62.94 (s, CF3). 
4-Chloro-1-trimethylsilylethynylbenzene (20e). 4-Chloroiodobenzene 19e was treated with 
CuI, (Ph3P)2PdCl2, Na ascorbate and Me3SiCCH in THF and Et3N, as for the synthesis of 
20c, to give 20e (96%) as a pale buff powder: mp 42-45C (lit.4 mp 43-45C); IR max 2157, 
1643, 1588, 825, 756 cm
-1
;
 1
H NMR (CDCl3)  0.24 (9 H, s, SiMe3), 7.26 (2 H, d, J = 8.8 Hz, 
2,6-C2), 7.37 (2 H, d, J = 8.9 Hz, 3,5-C2); 
13
C NMR (CDCl3)  0.00 (SiMe3), 95.47 (ethyne 2-
C), 121.78 (ethyne 1-C), 115.08 (4-C), 128.65 (2,6-C2), 133.29 (3,5-C2), 134.62 (1-C). 
1-Amino-4-trimethylsilylethynylbenzene (20g). 4-Iodoaniline 19g was treated with CuI, 
(Ph3P)2PdCl2, Na ascorbate and Me3SiCCH in THF and Et3N, as for the synthesis of 20c, to 
give 20g (74%) as an off-white solid: mp 94-98C (lit.5 mp 93-95C); IR max 3467, 2158, 
1622, 1510 cm
-1
; 
1
H NMR (CDCl3)  0.22 (9 H, s, SiMe3), 3.77 (2 H, br, NH2), 6.56 (2 H, d, J 
= 8.6 Hz, 2,6-H2), 7.27 (2 H, d, J = 8.2 Hz, 3,5-H2); 
13
C NMR (CDCl3)  -0.002 (SiMe3), 
91.22 (ethyne 2-C), 105.86 (ethyne 1-C), 112.45 (4-C), 114.38 (2,6-C2), 133.24 (3,5-C2), 
146.63 (1-C). 
(4-Phenylmethoxyoxyphenylethynyl)trimethylsilane (20h). Compound 19h was treated 
with CuI, (Ph3P)2PdCl2, Na ascorbate and Me3SiCCH in THF and Et3N, as for the synthesis 
of 20c, to give 20h (92%) as a white solid: mp 45-47°C (lit.
6
 mp 50C); IR max 2157, 1602 
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cm
-1
; 
1
H NMR (CDCl3)  0.25 (9 H, s, SiMe3), 5.06 (2 H, s, CH2), 6.89 (2 H, d, J = 6.8 Hz, 
3,5-H2), 7.25-7.40 (7 H, m, 2,6-H2, Ph 2,3,4,5,6-H5); 
13
C NMR (CDCl3)  -0.002 (SiMe3), 
69.96 (CH2), 92.50 (ethyne 2-C), 105.09 (ethyne 1-C), 114.71 (3,5-C2), 115.25 (1-C), 127.39 
(Ph 2,6-C2), 128.01 (Ph 4-C), 128.55 (Ph 3,5-C2), 133.42 (2,6-C2), 136.54 (Ph 1-C), 158.87 
(4-C). 
4-(Trimethylsilylethynyl)pyridine (20l). CuI (95 mg, 0.50 mmol), (Ph3P)2PdCl2 3 (174 mg, 
0.25 mmol), Na ascorbate (98 mg, 0.50 mmol) and 4-bromopyridine hydrochloride 22 (970 
mg, 5.0 mmol) were placed in a flask, which was degassed and filled with Ar. Pr
i
2NH (10 
mL) and THF (10 mL) were added. The mixture was stirred at 40C for 30 min. Me3SiC≡CH 
(532 mg, 5.0 mmol) was added and the mixture was stirred at 40C for 10 h. Evaporation and 
chromatography (petroleum ether / EtOAc 5:1 → 3:1) gave 20l (767 mg, 89%) as a pale buff 
oil (lit.
7
 yellow liquid); 
1
H NMR (CDCl3)  0.27 (9 H, s, SiMe3), 7.29 (2 H, d, J = 4.4 Hz, 3,5-
H2) 8.55 (2 H, d, J = 4.4 Hz, 2,6-H2); 
13
C NMR (CDCl3)  -0.002 (SiMe3), 100.24 (ethyne 2-
C), 102.31 (ethyne 1-C), 126.16 (3,5-C2), 131.52 (4-C), 150.03 (2,6-C2). 
1-Ethynyl-4-methoxybenzene (21c). Compound 20c (1.00 g, 4.9 mmol) in THF (100 mL) 
was stirred with Bu4NF in THF (1.0 M, 10 mL) for 16 h. Saturated aq. NaHCO3 was added 
and the mixture was extracted (Et2O, 3 ). Drying and chromatography (petroleum ether / 
EtOAc 19:1) gave 21c (595 mg, 92%) as a pale yellow oil (lit.
8
 oil): IR max 2158, 1607, 
1570, 1507 cm
-1
; 
1
H NMR (CDCl3)  2.98 (1 H, s, CCH), 3.80 (3 H, s, Me), 6.83 (2 H, d, J = 
9.5 Hz, 3,5-H2), 7.42 (2 H, d, J = 9.4 Hz, 2,6-H2); 
13
C NMR (CDCl3)  55.20 (OMe), 67.89 
(ethyne 2-C), 83.60 (ethyne 1-C), 113.88 (2,6-C2), 114.14 (4-C), 133.52 (3,5-C2), 159.90 (1-
C). 
1-Ethynyl-4-trifluoromethylbenzene (21d). Compound 20d was treated with Bu4NF, as for 
the synthesis of 21c, to give 21d (66%) as a colourless oil (lit.
9
 oil): IR max 1519, 1323 cm
-1
; 
1
H NMR (CDCl3)  3.18 (1 H, s, CCH), 7.58 (4 H, s, 2,3,5,6-H4), 
13
C NMR (CDCl3)  79.51 
(ethyne 2-C), 82.13 (ethyne 1-C), 123.81 (q, J = 288 Hz, CF3), 125.24 (2,6-C2), 125.88 (4-C), 
130.57 (q, J = 33 Hz, 4-C), 132.33 (3,5-C2); 
19
F NMR (CDCl3)  -62.96 (s, CF3). 
1-Chloro-4-ethynylbenzene (21e). Compound 20e was treated with Bu4NF, as for the synth-
esis of 21c, to give 21e (57%) as a pale amber powder: mp 41-44C (lit.10 mp 43-44.5C): IR 
max 2154, 1645, 1589, 1488, 756 cm
-1
; 
1
H NMR (CDCl3)  3.09 (1 H, s, CCH), 7.29 (2 H, 
d, J = 8.8 Hz, 3,5-H2), 7.41 (2 H, d, J = 8.9 Hz, 2,6-H2); 
13
C NMR (CDCl3)  78.07 (ethyne 2-
C), 85.45 (ethyne 1-C), 120.55 (4-C), 128.61 (3,5-C2), 133.28 (2,6-C2), 134.86 (1-C). 
1-Amino-4-ethynylbenzene (21g). Compound 20g (423 mg, 2.2 mmol) in THF (100 mL) 
was stirred with Bu4NF in THF (1.0 M, 6.7 mL) for 16 h at 35C. Saturated aq. NaHCO3 was 
added. The mixture was extracted (Et2O, 3 ). Drying and chromatography (petroleum ether / 
EtOAc 1:3) gave 21g (230 mg, 81%) as a pale green powder: mp 81-85C (lit.11 mp 88-90C): 
IR max 3486, 3388, 2095, 1619, 1513 cm
-1
; 
1
H NMR (CDCl3)  2.95 (1 H, s, CCH), 3.79 (2 
H, s, NH2), 6.58 (2 H, d, J = 7.6 Hz, 2,6-H2), 7.28 (2 H, d, J = 7.7 Hz, 3,5-H2); 
13
C NMR 
(CDCl3)  74.79 (ethyne 2-C), 84.32 (ethyne 1-C), 111.34 (4-C), 114.52 (2,6-C2), 133.41 
(3,5-C2), 146.95 (1-C). 
4-Ethynylpyridine (21l). Compound 20l (2.30 g, 13.1 mmol) in THF (30 mL) was stirred at 
40°C with Bu4NF in THF (1.0 M, 30 mL) for 10 h. Sat. aq. NaHCO3 was added and the 
mixture was extracted (EtOAc, 3 ). Drying, evaporation and chromatography (petroleum 
ether / EtOAc 3:1) gave 21l (550 mg, 42%) as an off-white powder with a strong unpleasant 
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odour: mp 51-54°C (lit.
12
 62-63°C); IR max 3378, 1641, 1594 cm
-1
; 
1
H NMR (CDCl3)  3.28 
(1 H, s, C≡CH), 7.33 (2 H, d, J = 5.8 Hz, 3,5-H2), 8.59 (2 H, m, 2,6-H2); 
13
C NMR (CDCl3)  
60.29 (ethyne 1-C), 80.88 (ethyne 2-C), 126.16 (3,5-C2), 130.25 (4-C), 149.74 (2,6-C2). 
2-Bromo-3-cyanopyridine (24). 2-Chloro-3-cyanopyridine 23 (3.68 mg, 26 mmol) was 
boiled under reflux with AcOH (100 mL) for 12 h. The evaporation residue, in THF (80 mL) 
and H2O (20 mL), was boiled under reflux for 4 h. Evaporation gave 3-cyanopyridin-2-one 
(3.12 g, quant.) as white crystals: mp 110-114C (lit.13 174-175C); 1H NMR  6.47 (1 H, t, J 
= 6.6 Hz, 5-H), 7.91 (1 H, dd, J = 6.5, 2.1 Hz, 4-H), 8.14 (1 H, dd, J = 7.0, 2.1 Hz, 6-H), 
11.48 (1 H, s, 1-H); 
13
C NMR  105.80 (3-C), 124.05 (5-C), 141.87 (CN), 144.50 (6-H), 
150.02 (4-C), 154.20 (2-C); MS m/z 143.0214 (M + Na)
+
 (C6H4N2NaO requires 143.0222). 
Bu4NBr (8.55 g, 26 mmol) and P2O5 (3.67 g, 26 mmol) were heated in PhMe (250 mL) at 
80°C for 30 min. The above 3-cyanopyridin-2-one (1.59 g, 13 mmol) was added and the 
mixture was boiled under reflux for 12 h. The mixture was cooled, poured into cold water and 
extracted (EtOAc, 2 ×). Drying and evaporation gave 24 (2.24 g, 94%) as off-white crystals: 
mp 114-118C (lit.14 mp 105C); IR max 2236, 1574, 1550, 1472 cm
-1
; 
1
H NMR (CDCl3)  
7.42 (1 H, dd, J = 7.7, 4.8 Hz, 5-H), 8.01 (1 H, dd, J = 7.8, 2.0 Hz, 4-H), 8.57 (1 H, dd, J = 
4.9, 2.0 Hz, 6-H); 
13
C NMR  114.27 (3-C), 115.63 (CN), 122.37 (5-C), 142.53 (4-C), 143.84 
(2-C), 152.92 (6-C). 
3-Bromopyridine-4-carboxylic acid (31). 3-Bromopyridine 30 (164 mg, 1.0 mmol) was 
added to LiNPr
i
2 in dry THF (1.0 M, 15 mL, 1.5 mmol) and the mixture was stirred at -78°C 
for 30 min under Ar. Crushed solid CO2 was added under Ar, and the cooling was removed. 
The mixture was stirred until reaching 20C. Water (10 mL) was added. The organic solvents 
were evaporated. The solution was washed thrice with Et2O. Aq. HCl (9 M) was added to pH 
3. The mixture was stirred for 1 h and extracted (EtOAc, 3 ). The combined extracts were 
washed (brine) and dried. Evaporation gave 31 (20 mg, 10%) as white needles: mp 175-176ºC 
(decomp.) (lit.
15
 mp 240C); 1H NMR  7.71 (1 H, d, J = 4.8 Hz, 6-H), 8.70 (1 H, d, J = 4.9 
Hz, 5-H), 8.91 (1 H, s, 2-H) 12.56 (1 H, br, OH); 
13
C NMR (CDCl3)  117.26 (4-C), 123.77 
(6-C), 148.94 (5-C), 152.61 (2-C), 165.00 (C=O), 166.07 (3-C); MS m/z 202 / 200 (M – H)-. 
3-Bromopyridine-4-carboxamide (32) and ethyl 3-bromopyridine-4-carboxylate (33). 
EtO2CCl (0.58 g, 5.4 mmol) was added dropwise to an ice-cold mixture of 31 (1.00 g, 4.6 
mmol), dry THF (15 mL) and dry Et3N (1.0 mL). The mixture was stirred for 1 h at 0ºC, then 
NH3 was bubbled through the suspension for 15 min. The mixture was filtered. The solids 
were washed with hot Me2CO. The solvent was evaporated from the combined filtrate and 
washings. Recrystallisation (EtOH) gave 32 as an off-white powder (777 mg, 78%): mp 149-
150ºC; 
1
H NMR (CDCl3)  7.48 (1 H, d, J = 4.8 Hz, 5-H), 7.88 (1 H, br, NH), 8.11 (1 H, br, 
NH), 8.65 (1 H, d, J = 4.8 Hz, 6-H), 8.84 (1 H, s, 2-H); 
13
C NMR (CDCl3)  116.82 (3-C), 
122.73 (5-C), 146.02 (4-C), 148.58 (6-C), 151.68 (2-C), 167.03 (C=O); MS m/z 224.9469 (M 
+ Na)
+
 (C6H5
81
BrN2NaO requires 224.9457), 222.9485 (M + Na)
+
 (C6H5
79
BrN2NaO requires 
222.9477). Evaporation of the solvent from the mother liquor gave 33 (60 mg, 5%) as a 
yellow liquid: 
1
H NMR (CDCl3)  1.41 (3 H, t, J = 7.2 Hz, Me), 4.43 (2 H, q, J = 7.3 Hz, 
CH2), 7.59 (1 H, d, J = 4.9 Hz, 5-H), 8.59 (1 H, d, J = 4.9 Hz, 6-H), 8.83 (1 H, s, 2-H); 
13
C 
NMR (CDCl3)  14.04 (Me), 62.33 (CH2), 118.71 (3-C), 124.15 (5-C), 139.34 (4-C), 148.41 
(6-C), 153.64 (2-C), 164.47 (C=O); MS m/z 253.9623 (M + Na)
+
 (C8H8
81
BrNNaO2 requires 
253.9611), 251.9638 (M + Na)
+
 (C8H8
79
BrNNaO2 requires 251.9631), 224.9469 (M + H)
+
 
(C6H5
81
BrN2O requires 224.9457), 222.9485 (M + H)
+
 (C6H5
79
BrN2O requires 222.9477). 
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3-Bromo-4-cyanopyridine (34). Compound 32 (687 mg, 3.4 mmol) was stirred at reflux with 
POCl3 (5.0 mL) for 2 h. The mixture was cooled, poured onto ice (100 g) and neutralised with 
aq. NaOH (5 M, 60 mL). The mixture was extracted Et2O (2 ×). The combined extracts were 
washed (sat. aq. NaHCO3), treated with charcoal and filtered. Evaporation and recrystallisat-
ion (petroleum ether) gave 34 as an off-white powder (292 mg, 42%): mp 79-81ºC (lit.
16
 mp 
96.6-98.2ºC); 
1
H NMR (CDCl3)  7.53 (1 H, d, J = 4.9 Hz, 5-H), 8.69 (1 H, d, J = 4.9 Hz, 6-
H), 8.92 (1 H, s, 2-H); 
13
C NMR (CDCl3)  114.79 (C≡N), 122.14 (4-C), 124.17 (3-C), 
126.75 (5-C), 148.76 (6-C), 152.69 (2-C); MS m/z 182.9541 (M + H)
+
 (C6H4N2
79
Br requires 
182.9552). 
1,3-Bis(4-methylphenyl)propane-1,3-dione (37b). NaH (2.00 g, 50 mmol, 60% in oil) was 
washed free from oil with dry hexane (10 mL) at 0ºC under Ar. Dry THF (30 mL) was added, 
followed by methyl 4-methylbenzoate (3.30 g, 22 mmol) in dry THF (10 mL) and 4-methyl-1-
acetylbenzene (2.66 g, 20 mmol) in dry THF (10 mL) at 0ºC under Ar. The suspension was 
stirred under reflux for 16 h. The mixture was cooled and filtered (Celite
®
). The solid was 
washed with EtOH (20 mL). The combined filtrates were poured into Et2O (20 mL) and aq. 
HCl (1 M, 20 mL). The aq. layer was extracted (Et2O, 2 ). The combined extracts were 
washed (brine, 3 ) and dried. Evaporation and recrystallisation (EtOH) gave 37b (2.50 g, 
50%) as yellow needles: mp 112-113ºC (lit.
17
 117-118ºC); 
1
H NMR (CDCl3) (enol)  2.46 (6 
H, s, 2 × Me), 6.84 (1 H, s, CH), 7.31 (4 H, d, J = 8.0 Hz, 2 × Ph 3,5-H2), 7.91 (4 H, d, J = 8.5 
Hz, 2 × Ph 2,6-H2); 
13
C NMR (CDCl3)  21.65 (2 × Me), 92.50 (CH), 127.18 (2 × Ph 2,6-C2), 
129.39 (2 × Ph 3,5-C2), 132.94 (2 × Ph 1-C), 143.11 (2 × Ph 4-C), 185.50 (C=O, C-OH); MS 
m/z 527.2193 (2 M + Na)
+
 (C34H32NaO4 requires 527.2188), 275.1055 (M + Na)
+
 
(C17H16NaO2 requires 275.1043). 
1,3-Bis(4-methoxyphenyl)propane-1,3-dione (37c). Methyl 4-methoxybenzoate was treated 
with 4-methoxy-1-acetylbenzene and NaH, as for the synthesis of 37b, to give 37c (46%) as 
an off-white powder: mp 110-111ºC (lit.
18
 111.5-113.5ºC); 
1
H NMR (CDCl3) (enol form)  
3.90 (6 H, s, 2 × Me), 6.76 (1 H, s, =CH), 6.99 (4 H, d, J = 8.5 Hz, 2 × Ph 3,5-H2), 8.01 (4 H, 
d, J = 9.0 Hz, 2 × Ph 2,6-H2); 
13
C NMR (CDCl3)  55.49 (2 × Me), 91.50 (=CH), 113.95 (2 × 
Ph 3,5-C2), 128.23 (2 × Ph 1-C), 128.09 (2 × Ph 2,6-C2), 163.03 (2 × Ph 4-C), 184.63 (C=O, 
C-OH); MS m/z 591.1950 (2 M + Na)
+
 (C34H32NaO8 requires 591.1984), 307.0933 (M + Na)
+
 
(C17H16NaO4 requires 307.0941). 
1,3-Bis(4-trifluoromethylphenyl)propane-1,3-dione (37d). Methyl 4-trifluoromethylbenz-
oate was treated with 4-trifluoromethyl-1-acetylbenzene and NaH, as for the synthesis of 37b, 
to give 37d (57%) as an off-white powder: mp 116-117ºC (lit.
19
 130ºC); 
1
H NMR (CDCl3) 
(enol)  6.91 (1 H, s, CH), 7.80 (4 H, s, 2 × Ph 3,5-H2), 8.12 (4 H, s, 2 × Ph 2,6-H2); 
13
C NMR 
(CDCl3)  94.15 (CH), 122.53 (2 × Ph 1-C), 124.66 (q, J = 270.8 Hz, 2× CF3,), 125.81 (q, J = 
3.5 Hz, 2 × Ph 3,5-C2), 127.62 (2 × Ph 2,6-C2), 134.26 (q, J = 32.8 Hz, 2 × Ph 4-C,), 184.70 
(C=O, C-OH); MS m/z 383.0495 (M + Na)
+
 (C17H10F6NaO2 requires 383.0477). 
1,3-Bis(4-chlorophenyl)propane-1,3-dione (37e). Methyl 4-chlorobenzoate was treated with 
4-chloro-1-acetylbenzene and NaH, as for the synthesis of 37b, to give 37e (68%) as a pale 
pink plates: mp 130-131ºC (lit.
20 
158-159ºC); 
1
H NMR (CDCl3) (enol)  6.70 (1 H, s, CH), 
7.40 (4 H, d, J = 8.5 Hz, 2 × Ph 3,5-H2), 7.85 (4 H, d, J = 8.5 Hz, 2 × Ph 2,6-H2); 
13
C NMR 
(CDCl3)  92.84 (CH), 128.49 (2 × Ph 2,6-C2), 129.01 (2 × Ph 3,5-C2), 133.69 (2 × Ph 1-C), 
138.87 (2 × Ph 4-C), 184.71 (C=O, C-OH); MS m/z 316.9863 (M + Na)
+
 
(C15H10
35
Cl
37
ClNaO2 requires 316.9923), 314.9948 (M + Na)
+
 (C15H10
35
Cl2NaO2 requires 
314.9950). 
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1,3-Bis(4-bromophenyl)propane-1,3-dione (37f). Methyl 4-bromobenzoate was treated with 
4-bromo-1-acetylbenzene and NaH, as for the synthesis of 37b, to give 37f (30%) as an off-
white powder: mp 198-200ºC (lit.
21
 197-198.5ºC); 
1
H NMR (CDCl3) (enol)  6.70 (1 H, s, 
CH), 7.55 (4 H, d, J = 9.0 Hz, 2 × Ph 3,5-H2), 7.77 (4 H, d, J = 8.5 Hz, 2 × Ph 2,6-H2); 
13
C 
NMR (CDCl3)  92.50 (CH), 126.80 (2 × Ph 4-C)128.63 (2 × Ph 2,6-C2), 131.99 (2 × Ph 3,5-
C2), 134.00 (2 × Ph 1-C), 184.71 (C=O, C-OH); MS m/z 406.8946 (M + Na)
+
 
(C15H10
81
Br2NaO2 requires 406.8901), 404.8966 (M + Na)
+
 (C15H10
79
Br
81
BrNaO2 requires 
404.8920), 402.8960 (M + Na)
+
 (C15H10
79
Br2NaO2). 
1,3-Di(pyridin-4-yl)propane-1,3-dione (37l). NaH (1.00 g, 25 mmol, 60% in oil) was 
washed free from oil with dry hexane (10 mL) at 0ºC under Ar. Dry THF (30 mL) was added. 
Methyl pyridine-4-carboxylate (1.51 g, 11 mmol) in dry THF (10 mL) and 4-acetylpyridine 
(1.21 g, 10 mmol) in dry THF (10 mL) at 0ºC under Ar were added. The suspension was 
stirred under reflux for 16 h. The cooled mixture was filtered (Celite
®
). The filtrate was 
poured into Et2O and water. Aq. HCl (9 M) was added to pH 4. The precipitate was collected 
and was washed (petroleum ether) to give 37l (960 mg, 42%) as pale buff needles: mp 158-
159ºC (lit.
22
 156-157ºC); 
1
H NMR (enol)  7.77 (1 H, s, CH), 8.34 (4 H, d, J = 5.0 Hz, 2 × 
pyridine 3,5-H2), 9.01 (4 H, d, J = 5.6 Hz, 2 × pyridine 2,6-H2); 
13
C NMR  97.50 (CH), 
121.84 (2 × pyridine 3,5-C2), 144.00 (2 × pyridine 4-C), 148.68 (2 × pyridine 2,6-C2), 184.0 
(C=O, C-OH); MS m/z 227.0826 (M + H)
+
 (C13H11N2O2 requires 227.0815). 
4-Phenylethynylbenzonitrile (42j). CuI (52 mg, 0.3 mmol), (Ph3P)4Pd (162 mg, 0.14 mmol), 
Na ascorbate (33 mg, 0.16 mmol) and 42f (500 mg, 2.75 mmol) were placed in a flask, which 
was degassed and filled with Ar. Pr
i
2NH (5 mL) and THF (10 mL) were added. The mixture 
was stirred at 40C for 30 min. PhC≡CH 21a (281 mg, 2.75 mmol) was added and the 
mixture was stirred at 40C for 16 h. Evaporation and chromatography (petroleum ether / 
EtOAc 199:1 → 99:1) gave 42j (480 mg, 87%) as an off-white powder: mp 84-86ºC (lit.3 mp 
78-79ºC); 
1
H NMR (CDCl3) d 7.33-7.41 (3 H, m, Ph 3,4,5-H3), 7.50-7.56 (2 H, m, Ph 2,6-H2), 
7.59-7.65 (NCPh 2,3,5,6-H4); 
13
C NMR (CDCl3) d 87.67 (ethyne 1-C), 93.72 (ethyne 2-C), 
111.39 (C≡N), 118.53 (NCPh 1-C), 122.15 (Ph 1-C), 128.19 (NCPh 4-C), 128.47 (Ph 3,5-C2), 
129.10 (Ph 4-C), 131.75 (Ph 2,6-C2), 132.02 (NCPh 2,6-C2), 132.03 (NCPh 3,5-C2). 
N-Methoxy-4-methylbenzimidamide (43b). 4-Methylbenzonitrile 42b (234 mg, 2.0 mmol) 
in MeOH (10 mL) was stirred with MeONH2.HCl (167 mg, 2.0 mmol) and Na2CO3 (212 mg, 
2.0 mmol) in water (5 mL) for 24 h. MeONH2.HCl (83.5 mg, 1.0 mmol) was added and the 
mixture was stirred for 2 d. The mixture was filtered. The evaporation residue, in CH2Cl2, was 
dried. Evaporation and recrystallisation (CHCl3 / petroleum ether) gave 43b (10 mg, 3%) as a 
white powder: mp 89-91°C (lit.
23
 85°C); 
1
H NMR (CD3OD)  2.43 (3 H, s, PhMe), 3.89 (3 H, 
s, OMe), 7.27 (2 H, d, J = 8.2 Hz, Ph 3,5-H2), 7.59 (2 H, d, J = 8.2 Hz, Ph 2,6-H2); 
13
C NMR 
(CDCl3)  21.82 (PhMe), 61.39 (OMe), 125.71 (2,6-C2), 129.28 (3,5-C2); MS m/z 165.1036 
(M + H)
+
 (C9H13N2O requires 165.1028). 
N-Methoxy-4-trifluoromethylbenzimidamide (43d). Compound 42d (342 mg, 2.0 mmol) in 
MeOH (5 mL) was added to MeONH2.HCl (167 mg, 2.0 mmol) and Na2CO3 (212 mg, 2.0 
mmol) in water (5 mL). The mixture was sonicated at 55°C for 30 min, then stirring continued 
at 20C for 20 h. MeONH2.HCl (83.5 mg, 1.0 mmol) was added and the mixture was stirred at 
25°C for 24 h. The mixture was filtered. The evaporation residue, in CH2Cl2, was dried. Evap-
oration and recrystallisation (CHCl3 / petroleum ether) gave 43d (85 mg, 20%) as a white 
powder: mp 92-94°C; 
1
H NMR (CD3OD)  3.95 (3 H, s, Me), 7.76 (2 H, d, J = 8.7 Hz, Ph 
3,5-H2), 7.90 (2 H, d, J = 8.8 Hz, Ph 2,6-H2), 13.99 (2 H, br, NH2); 
13
C NMR (CDCl3)  
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125.61 (3,5-C2), 127.32 (1-C), 129.24 (2,6-C2), 139.99 (4-C), 152.72 (C=N); MS m/z 
219.0730 (M + H)
+
 (C9H10FN2O requires 219.0745). 
N-Hydroxy-4-methylbenzimidamide (44b). 4-Methylbenzonitrile 42b (940 mg, 8.0 mmol) 
in EtOH (30 mL) was added to NH2OH.HCl (3.34 g, 48 mmol) and NaHCO3 (2.54 g, 24 
mmol) in water (30 mL) and the mixture was boiled under reflux for 3 h. The EtOH was 
evaporated and the residue was poured into water. The precipitate was collected, washed 
(water) and dried to give 44b (940 mg, 78%) as a white powder: mp 138-139°C (lit.
24
 136-
137°C); 
1
H NMR  2.37 (3 H, s, Me), 5.77 (2 H, br, NH2), 7.22 (2H, d, J = 8.0 Hz, Ph 3,5-
H2), 7.61 (2 H, d, J = 8.0 Hz, Ph 2,6-H2), 9.55 (1H, s, OH); 
13
C NMR  20.78 (Me), 125.24 
(2,6-C2), 128.60 (3,5-C2), 130.55 (1-C), 138.21 (4-C), 150.74 (C=N); MS m/z 151.0888 (M + 
H)
+
 (C8H11N2O requires 151.0871). 
N-Hydroxy-4-trifluoromethylbenzimidamide (44d). Compound 44d was prepared as 
previously described.
25 
4-Chloro-N-hydroxybenzimidamide (44e). Compound 44e was prepared as previously 
described.
25 
4-Bromo-N-hydroxybenzimidamide (44f). 4-Bromobenzonitrile 42f was treated with 
NH2OH.HCl and NaHCO3, as for the synthesis of 44b, to give 44f (90%) as a white powder: 
mp 140-141°C (lit.
26
 139-140°C); 
1
H NMR  5.90 (2 H, br, NH2), 7.60 (2 H, d, J = 8.8 Hz, Ph 
3,5-H2), 7.67 (2 H, d, J = 8.8 Hz, Ph 2,6-H2), 9.77 (1 H, s, OH); 
13
C NMR (HSQC / HMBC)  
122.06 (4-C), 127.39 (3,5-C2), 131.02 (2,6-C2), 132.56 (1-C), 149.97 (C=N); MS m/z 
216.9792 (M + H)
+
 (C7H8
81
BrN2O requires 216.9780), 214.9814 (M + H)
+
 (C7H8
79
BrN2O 
requires 214.9820). 
4-Amino-N-hydroxybenzimidamide (44g). 4-Aminobenzonitrile 42g (472 mg, 4.0 mmol) in 
EtOH (15 mL) was added to NH2OH.HCl (1.67 g, 24 mmol) and NaHCO3 (1.27 g, 12 mmol) 
in water (15 mL). The mixture boiled under reflux for 8 h and cooled. The EtOH was evap-
orated. The residue was poured into water and extracted (EtOAc, 3 ). The combined extracts 
were dried. Evaporation gave 44g (90 mg, 15%) as a white powder: mp 157-158°C (lit.
27
 166-
168°C); 
1
H NMR  5.30 (2 H, br, NH2), 5.62 (2 H, br, NH2), 6.57 (2 H, d, J = 8.6 Hz, Ph 3,5-
H2), 7.38 (2 H, d, J = 8.6 Hz, Ph 2,6-H2), 9.25 (1 H, s, OH); 
13
C NMR (CDCl3)  113.04 (3,5-
C2), 120.36 (1-C), 126.31 (2,6-C2), 149.57 (4-C), 151.49 (C=N); MS m/z 174.0649 (M + Na)
+
 
(C7H9N3NaO requires 174.0643), 152.0853 (M + H)
+
 (C7H10N3O requires 152.0824). 
N-Hydroxy-4-nitrobenzamidine (44k). 4-Nitrobenzonitrile 42k was treated with 
NH2OH.HCl and NaHCO3, as for the synthesis of 44b, to give 44k (97%) as a white powder: 
mp 174-176°C (lit.
28
 176°C); 
1
H NMR  4.62 (2 H, br, NH2), 7.95 (2 H, d, J = 8.7 Hz, Ph 2,6-
H2), 8.32 (2 H, d, J = 8.7 Hz, Ph 3,5-H2); 
13
C NMR  124.53 (3,5-C2), 128.19 (2,6-C2), 137.00 
(1-C), 149.00 (4-C), 163.00 (C=N); MS m/z 182.0562 (M + H)
+
 (C7H8N3O3 requires 
182.0566). 
N-Hydroxypyridine-4-carboximidamide (44l). 4-Cyanopyridine 42l was treated with 
NH2OH.HCl and NaHCO3, as for the synthesis of 44b, to give 44l (83%) as a white powder: 
mp 181-184°C (lit.
29
 178-179°C); 
1
H NMR (CDCl3)  6.04 (2 H, br, NH2), 7.69 (2 H, d, J = 
4.6 Hz, 3,5-H2), 8.62 (2 H, d, J = 4.8 Hz, 2,6-H2), 10.08 (1 H, s, OH); 
13
C NMR (CDCl3)  
121.9 (3,5-C2), 143.07 (4-C), 150.37 (2,6-C2), 152.22 (C=N); MS m/z 138.0683 (M + H)
+
 
(C6H8N3O requires 138.0667). 
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4-Methylbenzimidamide (45b). Compound 44b (150 mg, 1.0 mmol) was boiled under reflux 
with HCOONH4 (403 mg, 6.3 mmol) and Pd/C (10%, 150 mg) in AcOH (5 mL) for 4 d under 
Ar. The cooled mixture was filtered (Celite
®
). Aq. NaOH (1.0 M, 20 mL) was added to the 
evaporation residue and the mixture was extracted (EtOAc, 3 ). Drying and evaporation gave 
44b (82 mg, 61%) as a white powder: mp 53-55°C (lit.
30
 68°C); 
1
H NMR  2.42 (3 H, s, Me), 
6.72 (3 H, br, NH + NH2), 7.25 (2 H, d, J = 8.4 Hz, Ph 3,5-H2), 7.72 (2 H, d, J = 8.3 Hz, Ph 
2,6-H2); 
13
C NMR  20.08 (Me), 126.46 (2,6-C2), 128.56 (3,5-C2), 133.16 (1-C), 139.44 (4-
C), 162.57 (C=N); MS m/z 135.1018 (M + H)
+
 (C8H11N2 requires 135.0922). 
4-Trifluoromethylbenzimidamide (45d). Compound 45d was prepared as previously 
described.
25 
4-Chlorobenzimidamide (45e). Compound 45e was prepared as previously described.
25 
4-Bromobenzimidamide (45f). Compound 44f was treated with HCOONH4 and Pt/C, as for 
the synthesis of 45e, to give 45f (94 mg, 68%) as a white powder: mp 257-259°C (lit.
31
 258.5-
259.5°C); 
1
H NMR  7.51 (2 H, br, NH2), 7.53 (2 H, d, J = 7.6 Hz, 3,5-H2), 7.79 (2 H, d, J = 
7.2 Hz, 2,6-H2), 7.93 (1 H, br, NH); 
13
C NMR  126.73 (3,5-C2), 128.22 (2,6-C2), 129.59 (4-
C), 131.20 (1-C), 166.90 (C=N); MS m/z 200.9851 (M + H)
+
 (C7H8
81
BrN2 requires 200.9851), 
198.9877 (M + H)
+
 (C7H8
79
BrN2 requires 198.9871). 
4-Aminobenzimidamide (45g). Compound 44g (151 mg, 1.0 mmol) was stirred under reflux 
in AcOH (5 mL) with Pd/C (1%, 362 mg) and HCOONH4 (800 mg, 12.6 mmol) for 4 d, 
before being cooled and filtered (Celite
®
). The evaporation residue was basified with aq. 
NaOH (5 M, 20 mL) and extracted thrice with EtOAc. Drying and evaporation gave 45g (80 
mg, 59%) as a white powder: mp 200-201°C (lit.
32
 171°C); 
1
H NMR  6.70 (3 H, br, NH & 
NH2), 7.35 (2 H, br, NH2), 7.66 (2 H, d, J = 8.6 Hz, Ph 3,5-H2), 7.73 (2 H, d, J = 8.6 Hz, Ph 
2,6-H2); 
13
C NMR  117.80 (3,5-C2), 127.21 (2,6-C2), 133.0 (1-C), 140.0 (4-C), 152.0 (C=N); 
MS m/z 136.0898 (M + H)
+
 (C7H10N3 requires 136.0875). 
4-Phenylethynylbenzimidamide (45j). NaOMe (134 mg, 2.5 mmol) was stirred under reflux 
for 2 h with 44j (480 mg, 2.36 mmol) in dry MeOH (15 mL). NH4Cl (278 mg, 5.2 mmol) was 
added and stirring under reflux continued for 2 h. Evaporation and recrystallisation (water) 
gave 45j (355 mg, 68%) as an off-white powder: mp 90-91ºC; 
1
H NMR d 7.51-7.54 (3 H, m, 
Ph 3,4,5-H3), 7.67 (2 H, m, Ph 2,6-H2), 7.81 (2 H, m, amidine Ph 2,6-H2), 7.89 (1 H, br, NH), 
7.97 (2 H, m, amidine-Ph 3,5-H2), 9.06 (1 H, br, NH), 9.45 (1 H, br, NH); 
13
C NMR d 88.30 
(ethyne 1-C), 93.60 (ethyne 2-C), 111.05 (amidine Ph 1-C)118.44 (amidine Ph 4-C), 121.39 
(Ph 1-C), 128.88 (Ph 3,4,5-C3), 129.55 (Ph 4-C), 131.63 (Ph 2,6-C2), 132.15 (amidine Ph 3,5-
C2), 132.62 (amidine Ph 2,6-C2); MS m/z 242 (M + Na)
+
, 221.1090 (M + H)
+
 (C15H13N2 
requires 221.1073). 
Pyridine-4-carboximidamide (45l). Compound 44l (137 mg, 1.0 mmol) was boiled under 
reflux with Pd/C (1%, 150 mg) and HCOONH4 (400 mg, 6.3 mmol) in AcOH (5 mL) for 4 d. 
The suspension was filtered (Celite
®
). The evaporation residue was basified with aq. NaOH (5 
M, 20 mL) and extracted (EtOAc, 3 ). Evaporation and drying gave 45l (30.5 mg, 25%) as a 
white powder: mp >200°C (decomp.) (lit.
33
 235-238°C); 
1
H NMR  7.78 (2 H, d, J = 5.5 Hz, 
3,5-H2), 8.87 (2 H, d, J = 5.0 Hz, 2,6-H2), 9.52 (3 H, br, NH and NH2); 
13
C NMR  121.39 
(3,5-C2), 141.24 (4-C), 150.24 (2,6-C2), 166.38 (C=N); MS m/z 122.0710 (M + H)
+
 (C6H8N3 
requires 122.0718). 
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Data collection and refinement statistics for the tankyrase-2 crystal structures 
 
 
 
 
Compound 17a 12b 
PDB code 4W5I 4UX4 
Data   
Beam line Diamond I04-1 Diamond I04-1 
Wavelength (Å) 0.92000 0.92000 
Space group C2221 C2221 
Cell dimensions   
a, b, c (Å) 91.55, 98.12, 119.22 91.56, 97.89, 118.47 
Resolution (Å) 30-1.95 (2.00-1.95) 50-1.80 (1.85-1.80) 
Rmerge 13.2 (86.4) 6.3 (83.6) 
I / σI 9.87 (2.15) 18.80 (2.17) 
Completeness (%) 99.8 (100) 99.9 (100) 
Redundancy 6.7 (6.9) 6.8 (7.0) 
   
Refinement   
Rwork / Rfree 0.162/0.200 0.162/0.198 
B-factors   
Protein 27.2 28.3 
Inhibitor 18.1 34.3 
R.m.s.d.   
Bond lengths (Å) 0.011 0.012 
Bond angles () 1.4 1.5 
Ramachandran plot 
(%) 
  
Favoured regions 99.3 99.3 
Additionally 
allowed regions 
0.7 0.7 
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Examples of concentration-inhibition graphs for inhibition of TNKS-1 
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Examples of concentration-inhibition graphs for inhibition of TNKS-2 
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Examples of concentration-inhibition graphs for inhibition of PARP-1 KK-41 PARP-1
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